Ciprofloxacin Strongly Inhibits Clozapine Metabolism Two Case Reports

被引:31
作者
Brouwers, E. E. M. [1 ]
Sohne, M. [2 ]
Kuipers, S. [2 ]
van Gorp, E. C. M. [2 ]
Schellens, J. H. M. [3 ,4 ]
Koks, C. H. W. [1 ]
Beijnen, J. H. [1 ,3 ]
Huitema, A. D. R. [1 ]
机构
[1] Slotervaart Hosp, Dept Pharm & Pharmacol, Netherlands Canc Inst, NL-1066 EC Amsterdam, Netherlands
[2] Slotervaart Hosp, Dept Internal Med, Netherlands Canc Inst, NL-1066 EC Amsterdam, Netherlands
[3] Univ Utrecht, Fac Pharmaceut Sci, Dept Biomed Anal, Utrecht, Netherlands
[4] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
关键词
PAIN INSENSITIVITY; IN-VITRO; SCHIZOPHRENIA; RHABDOMYOLYSIS;
D O I
10.2165/0044011-200929010-00006
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
We report on two cases of drug-drug interactions between ciprofloxacin and clozapine. The first case was a 46-year-old male patient receiving a daily dose of clozapine 900 mg. He was admitted to hospital with urosepsis and was treated with a 5-day course of ciprofloxacin and amoxicillin. Two days after completion of antibacterial therapy, the patient developed symptoms of rhabdomyolysis. Clozapine therapy was discontinued and measurement of the patient's clozapine plasma concentration 1 day after cessation of clozapine therapy and 3 days after cessation of ciprofloxacin treatment showed that it was in excess of recommended therapeutic levels. The second patient was a 58-year-old male patient treated with a daily dose of clozapine 300 mg. He was admitted to hospital because of delirium and suspected urinary tract infection or pneumonia. Treatment with ciprofloxacin was initiated. Measurement of clozapine plasma concentrations prior to and 3 days after commencement of ciprofloxacin showed that clozapine concentrations doubled over that time period. We suggest that inhibition of cytochrome P450 (CYP) enzymes 1A2 and 3A4 by ciprofloxacin resulted in delayed clozapine metabolism and elevated clozapine plasma concentrations. This might cause severe adverse effects. We advise using another antibacterial agent or reducing the clozapine dose and monitoring clozapine levels when this antipsychotic agent is used in combination with ciproloxacin.
引用
收藏
页码:59 / 63
页数:5
相关论文
共 17 条
[1]
CLOZAPINE DISPOSITION COVARIES WITH CYP1A2 ACTIVITY DETERMINED BY A CAFFEINE TEST [J].
BERTILSSON, L ;
CARRILLO, JA ;
DAHL, ML ;
LLERENA, A ;
ALM, C ;
BONDESSON, U ;
LINDSTROM, L ;
DELARUBIA, IR ;
RAMOS, S ;
BENITEZ, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (05) :471-473
[2]
Clozapine toxicity in smoking cessation and with ciprofloxacin [J].
Brownlowe, Katherine ;
Sola, Christopher .
PSYCHOSOMATICS, 2008, 49 (02) :176-176
[3]
PAIN INSENSITIVITY IN SCHIZOPHRENIA - A NEGLECTED PHENOMENON AND SOME IMPLICATIONS [J].
DWORKIN, RH .
SCHIZOPHRENIA BULLETIN, 1994, 20 (02) :235-248
[4]
INHIBITORY POTENCY OF QUINOLONE ANTIBACTERIAL AGENTS AGAINST CYTOCHROME-P450IA2 ACTIVITY INVIVO AND INVITRO [J].
FUHR, U ;
ANDERS, EM ;
MAHR, G ;
SORGEL, F ;
STAIB, AH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (05) :942-948
[5]
Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism [J].
Granfors, MT ;
Backman, JT ;
Neuvonen, M ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (06) :598-606
[6]
Therapeutic monitoring of new antipsychotic drugs [J].
Hiemke, C ;
Dragicevic, A ;
Gründer, G ;
Hätter, S ;
Sachse, J ;
Vernaleken, I ;
Müller, MJ .
THERAPEUTIC DRUG MONITORING, 2004, 26 (02) :156-160
[7]
Proposal for a new tool to evaluate drug interaction cases [J].
Horn, John R. ;
Hansten, Philip D. ;
Chan, Lingtak-Neander .
ANNALS OF PHARMACOTHERAPY, 2007, 41 (04) :674-680
[8]
Bench-to-bedside review:: Rhabdomyolysis -: an overview for clinicians [J].
Huerta-Alardín, AL ;
Varon, J ;
Marik, PE .
CRITICAL CARE, 2005, 9 (02) :158-169
[9]
Iqbal Mohammad Masud, 2003, Ann Clin Psychiatry, V15, P33, DOI 10.3109/10401230309085668
[10]
Clozapine-associated neuroleptic malignant syndrome: Two new cases and a review of the literature [J].
Karagianis, JL ;
Phillips, LC ;
Hogan, KP ;
LeDrew, KK .
ANNALS OF PHARMACOTHERAPY, 1999, 33 (05) :623-630